Overview

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

Status:
Recruiting

Trial end date:
2021-09-01

Target enrollment:

Participant gender:

Summary

It is a trial to compare the efficacy and safety of Nab-paclitaxel plus Cisplatin vs Gemcitabine plus Cispatin as first line chemotherapy in advanced biliary tract cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborator:

CSPC Ouyi Pharmaceutical Co., Ltd.

Treatments:

Cisplatin
Gemcitabine
Paclitaxel